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Several polymorphisms of the transcription factor 4 (TCF4) have
been shown to increase the risk for schizophrenia, particularly
TCF4 rs9960767. This polymorphism is associated with impaired
sensorimotor gating measured by prepulse inhibition—an estab-
lished endophenotype of schizophrenia. We therefore investigated
whether TCF4 polymorphisms also affect another proposed endo-
phenotype of schizophrenia, namely sensory gating assessed by
P50 suppression of the auditory evoked potential. Although sen-
sorimotor gating and sensory gating are not identical, recent data
suggest that they share genetic fundamentals. In a multicenter
study at six academic institutions throughout Germany, we applied
an auditory P50 suppression paradigm to 1,821 subjects (1,023
never-smokers, 798 smokers) randomly selected from the general
population. Samples were genotyped for 21 TCF4 polymorphisms.
Given that smoking is highly prevalent in schizophrenia and af-
fects sensory gating, we also assessed smoking behavior, cotinine
plasma concentrations, exhaled carbon monoxide, and the Fager-
ström Test (FTND). P50 suppression was signiﬁcantly decreased in
carriers of schizophrenia risk alleles of the TCF4 polymorphisms
rs9960767, rs10401120rs, rs17597926, and 17512836 (P < 0.0002–
0.00005). These gene effects were modulated by smoking behavior
as indicated by signiﬁcant interactions of TCF4 genotype and
smoking status; heavy smokers (FTND score ≥4) showed stronger
gene effects on P50 suppression than light smokers and never-
smokers. Our ﬁnding suggests that sensory gating is modulated
by an interaction of TCF4 genotype with smoking, and both factors
may play a role in early information processing deﬁcits also in
schizophrenia. Consequently, considering smoking behavior may
facilitate the search for genetic risk factors for schizophrenia.
single nucleotide polymorphism | intermediate phenotype | nicotine |
gene–environment interaction
Recent large genomewide association studies (GWAS) iden-tiﬁed and consistently conﬁrmed that common variants of
the transcription factor 4 (TCF4) gene contribute to the risk of
schizophrenia (1–3). In these analyses, two single nucleotide
polymorphisms (SNPs) located in the intron of the TCF4 gene on
chromosome 18q21.1 (rs9960767, rs17512836) and an intragenic
SNP near the TCF4 gene (rs4309482) have shown the strongest
association with the disease (1–3). TCF4 is a class I basic helix–
loop–helix (bHLH) protein involved in the control of neuronal
and glial progenitor cells, which are important for the devel-
opment of the mammalian central nervous system (CNS) (4, 5).
The exact role of TCF4 in the brain and the functional activity
of these nonsynonymous TCF4 variants on the level of gene ex-
pression are not yet fully understood (4, 6). A recent postmortem
study suggested that the rs9960767 SNP is neither functional nor
affects mRNA expression in the adult human brain, indicating
that TCF4mutations may exert their effects on expression through
posttranscriptional effects or exclusively in a developmental con-
text (e.g., by gene–environment interactions) (7).
In a translational animal study, it was initially shown that
transgenic mice moderately overexpressing TCF4 in the post-
natal brain display profound reductions in sensorimotor gating
as measured by prepulse inhibition (PPI) of the acoustic startle
response (8), which is an established translational endopheno-
type of schizophrenia (9). Consequently, we recently investigated
the impact of the TCF4 rs9960767 SNP on PPI in humans and
found that the schizophrenia risk allele C of this SNP was
strongly associated with reduced PPI in two independent samples
of healthy volunteers and schizophrenia spectrum patients (10).
Auditory sensory gating, i.e., P50 suppression of the auditory
evoked potential (AEP) is another measure of gating function.
P50 gating is regarded as a useful endophenotype of schizophre-
nia and is conceptually related to, albeit not equivalent with,
sensorimotor gating as measured by PPI (9). In the classical au-
ditory conditioning-testing P50 paradigm (11), pairs of identical
auditory stimuli (conditioning stimulus S1 and test stimulus S2)
are presented at an interstimulus interval (ISI) of 500 ms, whereas
the cortical response to these stimuli is assessed via electroen-
cephalography (EEG). Normal subjects usually have a suppressed
P50 response to the second stimulus. Source localization studies
and intracerebral electrophysiological recordings suggest that
the generators of sensory gating are in the hippocampus, insula,
lateral temporal, temporo-parietal, and prefrontal cortex (PFC)
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(12–14). Auditory sensory gating has been conceptualized as an
important preattentive ﬁlter function that protects cognitive pro-
cesses from potentially interfering and irrelevant information (15).
Accordingly, P50 suppression has been related to attentional
performance, working memory, and behavioral inhibition (16–19).
Schizophrenia patients display diminished P50 suppression
(20–25), even if some studies failed to ﬁnd differences between
patients and controls (26–29). However, meta-analyses conﬁrmed
moderate to large effects of sensory gating deﬁcits in schizo-
phrenia across studies (30–32). The P50 suppression was sug-
gested as an endophenotype of schizophrenia (9) because it is
heritable (33–35), it is reduced in subjects with schizotypal per-
sonality disorder and in unaffected relatives of schizophrenia
patients (36–38), and decreased P50 suppression levels are
present in early stages of schizophrenia (39, 40). Moreover, P50
suppression deﬁcits have been repeatedly associated to SNPs of
the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7)
(41), whereas the initially reported impact of catechol-O-meth-
yltransferase (COMT) gene variations on P50 suppression (42)
was not replicated in three following studies (43–45). Despite the
fact that schizophrenia patients display both sensorimotor and
sensory gating abnormalities, and although both measures are
procedurally similar, they are usually not correlated and might be
regulated by distinct neuronal pathways (46–49). However, a re-
cent analysis from the Consortium on the Genetics of Schizo-
phrenia (COGS) suggested that both gating measures likely
share some genetic basis: PPI and P50 suppression were both
inﬂuenced by variations in CHRNA7, the neuregulin-1 (NRG1)
gene, and the ionotropic glutamate receptor δ2-subunit gene
(GRID2) (45, 50, 51). In the COGS study, the TCF4 gene was
not investigated and, thus, the impact of the TCF4 SNPs on
schizophrenia risk and sensorimotor gating (PPI) warrants also
an investigation of its inﬂuence on P50 suppression.
Because recent GWAS ﬁndings identiﬁed several TCF4 poly-
morphisms as genetic risk factors for schizophrenia (1–3), human
carriers of the TCF4 rs9960767 risk allele C showed reduced
gating abilities in the PPI paradigm (10), and auditory sensory
gating is an established endophenotype of schizophrenia (9), we
hypothesized that healthy carriers of TCF4 schizophrenia risk
polymorphisms would also display reduced auditory sensory gat-
ing as reﬂected in a decreased P50 suppression. Given that risk
gene variants for schizophrenia (including those identiﬁed in
TCF4) are common in the general population and because heri-
table variation of endophenotype measures is also present in
subjects not affected with schizophrenia (33–35), one can study
the possible association of risk variants with putative endophe-
notypes in healthy subjects. This approach offers a number of
advantages over classical case-control studies: (i) confounding
effects of illness and treatment are ruled out, (ii) larger samples
stratiﬁed for the presence or absence of possible environmental
moderators can be studied in a limited time, and (iii) indepen-
dence of conventional, phenotypic diagnostic criteria. Thus, pos-
itive ﬁndings for single gene variants in healthy controls can help
to discover biologically valid knowledge about previously un-
known mechanisms linked to this gene (52). To test our hypoth-
esis, we assessed a large and genetically homogeneous sample of
1,821 volunteers exclusively of German ancestry with an estab-
lished auditory sensory gating paradigm in the frame of a multi-
center study at six academic institutions throughout Germany. All
participants were genotyped for the 20 most signiﬁcant TCF4
SNPs from the recent GWAS of Ripke et al. (ref. 1; http://www.
broadinstitute.org/mpg/ricopili/; window 1.5Mb, threshold P <
1.0 × 10−4) and for the most signiﬁcant TCF4 SNP rs9960767
reported by Stefansson et al. (2) and Steinberg et al. (3). Given
that smoking is a critical confounding factor with regard to the
P50 suppression (53) and because schizophrenia patients are
frequently heavy smokers (54), we additionally investigated the
impact of smoking severity as a possible mediating factor on TCF4
gene effects on P50 suppression.
Results
One of the 21 TCF4 SNPs was monomorphic (rs17509991) and,
therefore, excluded from further analyses. All other SNPs were
in Hardy–Weinberg equilibrium (HWE) (Table S1) and partly in
strong linkage disequilibrium (LD) (Fig. S1).
Unless otherwise stated, we compared SNP risk allele carriers
against noncarriers throughout (10). Percent P50 suppression
was signiﬁcantly affected by 4 of the 20 TCF4 SNPs (Bonferroni-
corrected threshold P < 0.0024 for 21 markers) and smoking
status, whereas there was also a signiﬁcant genotype–smoking
interaction in each marker (Table 1). Given that the rs17597926
and the rs17512836 SNP showed almost perfect linkage dis-
equilibrium (LD, r2 = 0.99), only data of the rs17597926 SNP are
further presented. Remaining pairwise relationships showed
moderate LD between SNPs (Fig. 1). In each of the signiﬁcant
SNPs, carriers of the respective schizophrenia risk alleles dis-
played reduced auditory sensory gating (Fig. 2A). The signiﬁcant
interactions of the factors genotype and smoking status indicated
that the genotype effects were different among never, light, and
heavy smokers (Fig. 2B). Heavy smokers [Fagerström Test of
Nicotine Dependence (FTND) score ≥ 4] consistently showed
stronger TCF4 gene effects on P50 suppression (Cohen’s d =
0.63–1.04) than light smokers (d = 0.27–0.43) and never-smokers
(d = −0.04 to 0.06]. Bonferroni post hoc tests of the main effect
of smoking status replicated the ﬁnding shown in an overlapping
sample of the present population (53): In all tests, heavy smokers
displayed lower P50 suppression levels than light smokers (P =
0.014–0.006; d = 0.34–0.59) and never-smokers (P = 4.4 × 10−5
to 5.5 × 10−6; d = 0.55–0.76), whereas light smokers and never-
smokers did not signiﬁcantly differ (P = 0.070–0.482; d = 0.17–
0.21). The effect for the repeated factor electrode position alone
was not signiﬁcant (all tests: F < 1.2), but it interacted with ge-
notype in the analyses of rs9960767 [F(1,1812) = 7.10; P = 0.008;
ηp2 = 0.004] and rs10401120 [F(1,1799) = 6.94; P = 0.008; ηp2 =
0.004], indicating that the TCF4 genotype effect was more evi-
dent at the frontal electrode (Fz) (Fig. S2). Further interactions
between factors and covariates were not signiﬁcant. Finally,
the covariate age (P = 4.1 × 10−14 to 7.7 × 10−15, ηp2 = 0.033–
0.035) revealed a signiﬁcant effect, whereas the impact of sex,
study center, cotinine plasma level, and longitude/latitude of
study center was not signiﬁcant (all tests: F < 1.25). As shown
before (53), sensory gating increases with age (see also correla-
tion analyses in SI Discussion). Longitude and latitude were in-
cluded in the analysis to control for subtle population differences
between the sampling sites. Because only SNP rs9960767 presents
a reasonable number of rare homozygotes (n > 10), the analysis
of this marker was repeated in a threefold genotype factor design.
However, the genotype effects and genotype–smoking interac-
tions remained largely the same (Fig. S3).
The genotype groups of the signiﬁcant SNPs did not differ re-
garding any demographic data, smoking parameters, or psycho-
metric scales (Table S2). Thus, the effects observed because of
risk allele carrier-ship could not be explained by demographical
stratiﬁcation effects.
As shown in Table S3, the four TCF4 SNPs showing signiﬁcant
association with P50 suppression did not signiﬁcantly affect the
amplitude of the P50 AEP neither on the response to the ﬁrst
click (S1) nor to the second click (S2). Analyses of the difference
and the ratio of P50 amplitudes as further measures of auditory
sensory gating revealed the same effects as in the analysis of
percent P50 suppression. Again, the TCF4 genotype effect on
P50 suppression was most pronounced at the Fz electrode.
Correlations of P50 parameters with demographic and smoking
variables are shown in SI Discussion and Table S4.
To assess the association between the reduced levels of P50
suppression and TCF4 risk allele carrier-ship, odds ratios (OR)
were calculated. If clinical criteria of one and two SDs were
applied to deﬁne low P50 suppression phenotypes, all of these
phenotypes showed signiﬁcant associations with the respective
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1118051109 Quednow et al.
four TCF4 risk-alleles within the total sample (range OR = 1.81–
2.58) and within heavy smokers (range OR = 3.21–7.60) but not
within the never-smokers (range OR = 1.23–1.75) (Table S5). At
each criterion, the odds ratios were highest in heavy smokers and
lowest in never-smokers, whereas light smokers were interme-
diate (range OR = 2.44–2.78). Moreover, there was no associ-
ation of the four signiﬁcant TCF4 SNPs with the smoking
phenotype (Table S6).
Discussion
In an endophenotype-based association study approach, we in-
vestigated the impact of TCF4 schizophrenia risk SNPs on an
established psychophysiological endophenotype of schizophrenia.
We could demonstrate that carrier-ship of risk alleles at four
TCF4 SNPs (rs9960767, rs17512836, rs17597926, and rs10401120)
were signiﬁcantly associated with reduced auditory sensory gat-
ing as measured by P50 suppression of the AEP. Noteworthy,
two of these SNPs (rs9960767, rs17512836) were among the top
markers associated with schizophrenia with genomewide signiﬁ-
cance in recent large GWAS meta-analyses (1, 2), whereas SNP
rs17597926 was the marker in the TCF4 gene showing the second
smallest P value in one of these studies (1). Markers rs17512836
and rs17597926 were in strong LD (r2 = 0.99), thus representing
essentially the same association signal. Further pairwise LD
relationships were moderate (r2 = 0.38–0.64). Interestingly, the
genotypic effects of each SNP were strongly modulated by
smoking behavior with only smokers showing reliable TCF4-P50
suppression associations, whereas the genetic effect was small or
not present in never-smokers. Moreover, genotype–smoking in-
teractions were dose-related because TCF4 SNP genotype effects
ampliﬁed with increasing smoking severity.
TCF4 belongs to a subfamily of bHLH transcriptional regu-
lators that recognizes the Ephrussi-box (E-box) binding site on
the DNA that usually lies upstream of a gene in a promoter region
(55). At early developmental stages, E-box transcription factors
such as TCFE2a, TCF12, and TCF4 show widespread expression
throughout the brain, but only TCF4 displays sustained expres-
sion in the adult brain of mice, which is most prominent in the
cerebellum, hippocampus, and cortex (8, 56). TCF4-null knock-
out mice die in the ﬁrst 24 h after birth and display brain-
stem abnormalities (4, 57). Haploinsufﬁciency of the TCF4 gene
in humans causes the Pitt-Hopkins syndrome—an autosomal-
dominant neurodevelopmental disorder characterized by severe
mental and motor retardation, microcephaly, epilepsy, facial
dysmorphisms, and intermittent hyperventilation—reﬂecting that
TCF4 is critical for the development of the mammalian CNS
(6, 55). Thus, the respective TCF4 polymorphisms might have a
subtle impact on brain development that contributes to gating
abnormalities and that increases the risk for schizophrenia.
The present results are in line with our previous ﬁndings that
the schizophrenia risk allele C of the TCF4 rs9960767 SNP is
associated with diminished sensorimotor gating as measured by
PPI (8, 10). Although PPI and P50 suppression are not correlated
and might be regulated—at least in part—by distinct neuronal
mechanisms (46–49), recent work suggests that they nevertheless
might share some common genetic pathways (41, 45, 50, 51).
However, the modifying inﬂuence of smoking on the effect of
TCF4 shown here was not present in our previous investigation
Table 1. The effects of TCF4 SNP risk allele carrier-ship and smoking status on percent P50 suppression of the auditory evoked
potential (averaged across electrode positions Fz and Cz)
TCF4
genotype
Position on
chromosome
18q21.1
Allele frequency number, %
Total
n
Schizohrenia
risk allele*
Genetic
model†
Effect on P50 suppression
Common
homocygotes Heterozygotes
Rare
homocygeotes
Factor
genotype
(df = 1)
Factor
Smoking
(df = 2)
Interaction
smoking–
genotype
(df = 2)
rs9960767‡ Intron
53155002
AA 1,610,
88.4%
AC 199,
10.9%
CC 12,
0.7%
1,821 C AA vs. AC+CC F = 16.7;
P = 4.5 × 10−5;
ηp
2= 0.010
F = 11.7;
P = 8.7 × 10−6;
ηp
2= 0.013
F = 7.1;
P = 0.001;
ηp
2= 0.008
rs10401120 Intron
53192498
CC 1,647,
90.9%
CT 156,
8.6%
TT 9,
0.5%
1,812 T CC vs. CT+TT F = 15.9;
P = 6.9 × 10−5;
ηp
2= 0.009
F = 10.9;
P = 1.9 × 10−5;
ηp
2= 0.013
F = 5.8;
P = 0.003;
ηp
2= 0.007
rs17597926§ Intron
53205938
GG 1,723,
94.6%
GA 95,
5.2%
AA 3,
0.2%
1,821 A GG vs. GA+AA F = 14.5;
P = 1.4 × 10−4;
ηp
2= 0.008
F = 9.5;
P = 7.9 × 10−5;
ηp
2= 0.011
F = 4.9;
P = 0.008;
ηp
2= 0.006
rs17512836{ Intron
53194961
TT 1,721,
94.6%
TC 95,
5.2%
CC 3,
0.2%
1,819 C TT vs. TC+CC F = 13.9;
P = 2.0 × 10−4;
ηp
2= 0.008
F = 9.2;
P = 1.1 × 10−4;
ηp
2= 0.011
F = 4.4;
P = 0.013;
ηp
2= 0.005
*According to Ripke et al. (1) and Stefansson et al. (2).
†ANCOVA with genotype (twofold), and smoking status (threefold) as ﬁxed factors, electrode position (twofold) as repeated factor, and age, sex, study cite,
cotinine plasma level, and longitude and latitude of the study centers as covariates.
‡Most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Stefansson et al. (2).
§Second most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Ripke et al. (2).
{Most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Ripke et al. (1).
Fig. 1. Pairwise linkage disequilibrium (LD), as measured by r2, of four TCF4
SNPs that were signiﬁcantly associated with percent P50 suppression.
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on TCF4 gene effects on PPI (10). The previously investigated
samples may have been too small and underpowered to reliably
examine the effects of smoking as a mediating factor on the
TCF4 gene effects on PPI. The potentially modifying effect of
smoking on TCF4 gene effects on PPI (and other schizophrenia
endophenotypes) should therefore be investigated in larger
samples. Finally, the TCF4 rs9960767 genotypic effect on PPI
displayed a much stronger effect size (Cohen’s d = 0.90) than the
mean effect on P50 suppression (d = 0.18–0.20). This difference
may be explained either by the “winner’s curse”—which means
that estimations of the genetic effect based on novel association
ﬁndings tend to be upwardly biased (58)—by the fact that P50
suppression usually displays a less beneﬁcial retest reliability
compared with PPI (21, 59), or by a differential impact of TCF4
on the underlying neural systems (or a mixture of these factors).
Interestingly, TCF4 genotype effects on P50 suppression were
more evident at the Fz than on the vertex electrode (Cz). Pre-
vious studies reported that the PFC substantially contributes
either to the sensory gating process per se (13) or at least to the
generation of the P50 amplitude (14). Additionally, data from
a recent EEG source localization study suggest that the sensory
gating deﬁcit of schizophrenia patients could be explained by
dysfunction of the dorsolateral PFC (60). Thus, TCF4 mutations
(in combination with smoking) might have a speciﬁc impact on
PFC function in schizophrenia.
How can the unexpected smoking–genotype interaction re-
garding P50 suppression be elucidated? There are at least two
possible scenarios: The ﬁrst is a hidden gene–gene interaction: In
this model, TCF4 SNPs interact with a hidden gene (or genes) so
that only the presence of two or more risk alleles is associated
with both smoking severity and P50 suppression, whereas the
TCF4 SNPs were exclusively associated with P50 suppression but
not with smoking. Promising candidates for the “hidden” SNPs
may lie in the CHRNA3-CHRNA5-CHRNB4 gene cluster coding
for α3, α5, and β4 nicotinic acetylcholine receptor (nAChR)
subtypes. SNPs from this gene cluster were reliably associated
with smoking behavior (61–63), and also with sensorimotor
gating (PPI) (64) and cognitive performance (65). SNPs of the
CHRNA7 would also be interesting candidates because of the
reported associations with P50 suppression and smoking behav-
ior (41, 66, 67).
The second, and maybe more appealing, explanation for the
present result pattern could be a gene–environment interaction,
in which smoking represents a long-lasting and ongoing envi-
ronmental inﬂuence. This interpretation would be in line with
the suggestion of Williams et al. (7) that the TCF4 schizophrenia
risk alleles may exert their effects on expression exclusively in a
developmental context because postmortem data of this study
suggested that SNP rs9960767 is neither functional nor affects
mRNA expression in the adult human brain. Furthermore, evi-
dence accumulates that risk SNPs might have signiﬁcant ex-
pression effects on other genes but not on the one in which they
are located (68). However, at this point, we can only hypothesize
which neurobiological mechanisms might underlie this smoking–
TCF4 interaction on P50 suppression: (i) Smoking-induced plas-
ticity of brainstem nAChR (69–72) in concert with subtle neuro-
developmental changes in pontine nuclei induced by TCF4 gene
variations (4) may affect P50 suppression. (ii) TCF4-induced
changes in the noradrenaline system (6, 55) might interact with
nicotine-induced changes of α7 nAChR function (73) when mod-
ulating P50 suppression. (iii) Nicotine may be involved in the meth-
ylation of DNA sequences leading to an epigenetic change of the
expression of the TCF4 gene (or other genes interacting with
TCF4) with functional consequences on early information pro-
cessing (74, 75).
Several studies have demonstrated that CHRNA7 promoter
variations are associated with schizophrenia and affect P50
suppression (41). The present study adds TCF4 mutations as
complementary genetic factors (or more exactly a TCF4–smok-
ing interaction) to the population variation in P50 suppression
and it has been shown that also TCF4 gene variations increase
the risk for schizophrenia (1–3). However, it should be noticed
that the explained variances of P50 suppression by the factors
TCF4 genotype (0.8–1.0%), smoking (1.1–1.3%), and age (3.3–
3.5%) as well as of the TCF4–smoking interaction (0.07–0.08%)
were rather small, reﬂecting that either many other genetic
factors might be involved or that P50 suppression may also have
a strong state-dependent part as it was suggested (33).
The question arises whether effects of population stratiﬁcation
might have inﬂuenced our results because we have not typed a
standard panel of ancestry-informative SNPs to control for strat-
iﬁcation effects. However, we aimed to build a genetically highly
homogeneous sample of subjects with an ancestry exclusively
from Germany, and we randomly selected our participants from
the general population to avoid possible stratiﬁcation effects. Ad-
ditionally, the European autosomal gene pool was recently found
to be rather small, especially in northern and middle Europe
subpopulations (76). Nevertheless, this study has shown a conti-
nent-wide correlation between geographic and genetic distance
along the north-south axis and, to a lesser extent, also along the
east-west axis (76). Therefore, we included longitude and latitude
of the study centers as covariates in our analyses to control for
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Fig. 2. The effects of three TCF4 SNPs (rs9960767, rs10401120, and rs17597926,
which was in almost complete linkage disequilibrium with rs17512836) on
percent P50 suppression of the auditory evoked potential (means and SEM;
adjusted for age, sex, study site, cotinine plasma level, and longitude and
latitude of the study center) averaged across the electrode positions Fz and Cz
(A), and stratiﬁed according to smoking behavior (never-smokers: n = 1,023,
light smokers: n = 466, and heavy smokers n = 332) (B). ***P < 2.0 × 10−4.
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even subtle population stratiﬁcation, which did not change our
results. We also explored regional differences in TCF4 SNP ge-
notype frequencies between study centers located in three areas of
Germany (North, Midwest, and South), but we found no signiﬁ-
cant differences between these regions (Fig. S4). Lastly, the TCF4
SNP allele frequencies of the present sample ﬁtted with the fre-
quencies of the European HapMap data (CEU), and none of the
investigated SNPs deviated from the HWE. Thus, the strong as-
sociation of TCF4 with auditory sensory gating is likely not ex-
plainable by population stratiﬁcation effects.
In conclusion, our results suggest that the schizophrenia risk
alleles of TCF4 variants interact with smoking behavior with
regard to auditory sensory gating, which is an established endo-
phenotype of schizophrenia. We hypothesized that this ﬁnding
could be interpreted as a gene–environment interaction with
plausible neurobiological explanations. If smoking behavior
strongly modulates the TCF4 SNP effects on a proposed endo-
phenotype of schizophrenia, it might also modulate the risk for
schizophrenia itself. We therefore suggest the investigation of
potential moderating effects of dimensional and binary measures
of smoking behavior on genetic risk factors of schizophrenia. In
case-control association studies, stratiﬁcation for smoking be-
havior may add power to yield stronger gene effects. Moreover,
it should be further explored whether nicotine use itself might
enhance the risk for schizophrenia as indicated by longitudinal
studies showing that beyond cannabis and alcohol use, early
consumption of tobacco increases the risk for psychosis (77, 78).
Finally, an extended endophenotype including electrophysio-
logical gating measures such as PPI or P50 suppression, smoking
behavior, and risk genes such as TCF4may be suitable as an early
indicator for a developing psychosis.
Materials and Methods
Participants. The study was carried out in the framework of the German
multicenter study: Nicotine: Physiological and Molecular Effect in the CNS
(53, 79). All subjects were randomly selected from the local general pop-
ulation of seven cities across Germany (Aachen, Berlin, Bonn, Düsseldorf,
Erlangen, Mainz, and Mannheim) via ofﬁcial residents’ registers and con-
tacted by letter with an invitation to participate in the study. Overall, n =
56,350 subjects were contacted, of whom n = 4,760 responded by phone and
completed an initial prescreening interview. Healthy subjects of German
origin who met the inclusion/exclusion criteria (SI Discussion) were invited
for a ﬁnal screening investigation, which included a lifetime smoking history
assessment, a medical examination, a standardized psychiatric interview
(SCID-I), a drug urine screening, exhaled carbon-monoxide (COHb) mea-
surement, and blood for routine clinical laboratory tests and genotyping. n =
2,442 subjects were ﬁnally included in the study. Across study sites, n = 468
subjects had either no electroencephalography (EEG) assessment (e.g., the
Mannheim center did not apply EEG) or displayed an insufﬁcient EEG data
quality, whereas n = 238 subjects either did not provide blood samples, their
DNA was not recoverable, or the genotyping failed, leaving a ﬁnal sample
of n = 1,821 participants (Table S2). The sample consisted of 1,023 never-
smokers (lifetime smoking <20 cigarettes), 466 light smokers FTND score <4),
and 332 heavy smokers (FTND ≥4).
The study was approved by the ethics committees of each study site’s
local university and was conducted according to the declaration of Helsinki.
Written informed consent was obtained from all subjects.
Study Procedures.Across all study sites, the studywas performed on the day of
study inclusion according to the same standard operating procedure in-
cluding regular monitoring with strict adherence to a ﬁxed time table. After
inclusion, subjects provided extensive demographical and smoking-related
information and answered a battery of questionnaires on smoking-related
behavior (for details, see SI Discussion), drug/alcohol consumption habits,
and personality (79). Afterward, a neuropsychological test battery and an
EEG investigation were performed (79). The EEG was obtained between 1:30
AM and 2:30 PM in all subjects. Subsequently, venous blood was obtained to
determine cotinine plasma levels and for genotyping. In smoking subjects,
the EEG was recorded between 1 and 3 h after the last cigarette smoked ad
libitum. Genotyping information is given in the SI Discussion.
P50 Auditory Double Click Paradigm. Subjects were instructed to keep their
eyes closed throughout the EEG experiment. Five minutes of continuous
resting EEG was recorded before the P50 auditory double-click paradigm,
which was based on the work of Adler et al. (80). One hundred pairs of two
250 sinus tones (clicks) of 2,000 Hz (50-ms duration including rise and fall
time) were administered binaurally via headphone at a 50-dB sound pres-
sure level. A ﬁxed ISI of 500 ms was chosen between paired clicks S1 and S2.
Between pairs of clicks, the intervals were (pseudo)randomized varying
between 5 and 9 s (mean 7 s). Subjects were instructed to stay awake and to
listen to the tones. EEG data acquisition and analysis is described in SI Dis-
cussion. The amplitudes of the event-related P50 potential (ﬁltered at 10–45
Hz, 12 dB) were calculated across electrodes by automatically locating the
most positive peak in the respective time window. The P50 response was the
most positive peak between 48 and 68 ms after stimulus onset (both after S1
and S2) (24). The P50 amplitude was measured relative to the preceding
negativity. For the analysis of P50 suppression, the percent P50 suppression
([1 − S2/S1] × 100), the difference of P50 amplitudes (S1 − S2), and the ratio
of P50 amplitudes (S2/S1) was used. Low value of the percent and the dif-
ference suppression as well as high values of the ratio indicate weak in-
hibition of the second click (i.e., no gating or ﬁltering) or low P50 amplitude
after the ﬁrst click. Fz and Cz electrodes were analyzed because previous
studies have shown that P50 suppression measured at these electrodes dis-
criminate best between schizophrenia patients and controls (23, 24, 81).
Details of the statistical analysis are given in the SI Discussion.
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SI Discussion
It should be noted that Steinberg et al. (1) recently analyzed the
TCF4 SNP rs9960767 in a large metaanalysis including the
Göttingen Research Association for Schizophrenia (GRAS) sam-
ple, which mainly consists of schizophrenia patients and controls
of German ancestry. Although the populationwide signiﬁcance
was replicated for this SNP, no signiﬁcant effect was found in the
GRAS sample. However, these contrary results might possibly be
explained by a lack of power because the Steinberg study ﬁnally
includes 18,206 cases and 42,536 controls compared with 1,041
cases and 1,144 controls in the GRAS sample (2). Furthermore,
in a previous meta-analysis of schizophrenia GWAS samples, a
German subsample from Bonn showed a signiﬁcant association
with rs9960767, whereas another German subsample from Mu-
nich at least revealed a strong trend for this marker (3).
Nevertheless, these mixed results point to the fact that the
TCF4 gene effects on schizophrenia are quite small and do not
have predictive value (2). However, a multivariate phenotype-
based association analysis of the GRAS sample revealed an in-
teresting trend for an association between TCF4 rs9960767 and
a dimensional schizophrenia phenotype that combines positive,
negative, and cognitive symptoms (2). In concert with the present
data this demonstrates that the (endo)phenotype-based ap-
proach could boost the power of a genetic study compared with
the approach of classical categorization of the mental illness by
using the current diagnostic manuals as used in classical case-
control studies (4).
Patricipants. Inclusion and exclusion criteria of the study are listed
below (for further details, see ref. 5):
Inclusion criteria.
i) Age: 18–65 y.
ii) Smoking status: current smoker (also occasional smoker with
a minimum of seven cigarettes per week/one cigarette per
day) or never-smoker (max. 20 cigarettes per lifetime).
iii) All grandparents of subjects were required to be born in
Germany or in a country adjacent to Germany.
iv) Mother-tongue level German.
v) Each participant must have been personally contacted by
letter (via ofﬁcial local residents’ registers).
Exclusion criteria.
i) Former smoker.
ii) Alcohol- or substance abuse within previous six months
(DSM-IV).
iii) Lifetime diagnosis of alcohol- or substance dependence
(DSM-IV).
iv) Other DSM-IV axis-1 psychiatric diagnosis within previous
6 mo.
v) Non-German origin (see inclusion criteria).
vi) No mother-tongue level German.
vii) Serious vision or hearing impairment.
viii) Pregnancy.
ix) CNS-relevant medication within previous 6 mo.
x) CNS-relevant (neurological/medical) illnesses lifetime.
Genotyping. DNA for genotyping was isolated from EDTA acid
anticoagulated blood by using the FlexiGene DNA Kit (Qiagen).
The TCF4 SNP (rs9960767) was analyzed by a Taqman assay
(Applied Biosystems). PCR ampliﬁcation was performed by using
10 ng of genomic DNA on the GeneAmp 9700 thermal cycler,
and ﬂuorescence intensity was read on the 7900HT Sequence
Detection System (Applied Biosystems). The other 20 TCF4
SNPs (rs4131791, rs4309482, rs8092679, rs9951150, rs11152369,
rs11874716, rs11875348, rs12966547, rs17511376, rs17512836,
rs17594526, rs17596974, rs17597926, rs9646596, rs9953930,
rs10401120, rs17594665, rs17594721, rs17596267) were analyzed
by applying the iPlex SNP genotyping assay (Sequenom) followed
by mass spectrometry (MALDI-TOF) on a MassArray Analyzer
Compact (Sequenom). Ten nanograms of genomic DNA were
used per multiplex reaction. Brieﬂy, following a locus-speciﬁc
PCR, a primer extension reaction was performed by using mass-
modiﬁed ddNTPs. After desalting, the products were spotted
onto a chip matrix and analyzed by MALDI-TOF. Clustering
and genotype calling was performed by using the MassARRAY
Typer v4.0 software (Sequenom). For quality control, the complete
sample was genotyped twice. Concordance among duplicate sam-
ples was 100%.
The minor allele frequencies of every investigated TCF4 SNP
in the total sample (n = 2,204) were comparable with the
HapMap-CEU population available at the National Center for
Biotechnology Information Web site (www.hapmap.org), and all
were distributed in accordance with the Hardy–Weinberg equi-
librium (HWE). The call rates for each SNP were >99.5%
(Table S1). Pairwise linkage disequilibrium (LD) relationships of
all SNPs (the monomorphic SNP rs17509991 was excluded) are
shown in Fig. S1.
EEG Data Acquisition and Analysis.EEG data were recorded either by
using a 32-channel EEG system from Brain Products (BrainAmp
DC; used in three study sites) or a Neuroscan (Synamps-2). A 32-
channel EEG cap (EasyCap) was used at all study sites. Sys-
tematic inspection across centers revealed no equipment-de-
pendent site effects on P50 (6). Twenty-nine scalp electrodes
were distributed according to the extended 10-20 system. Two
electrodes were placed at the outer canthi and above the lower
orbital portion of the orbicularis oculi muscle to detect hori-
zontal and vertical eye movements, respectively. One electrode
was attached to the subjects left wrist for recording the elec-
trocardiogram (ECG). Data were recorded relative to the Cz
reference. Sampling rate of the analog data were 250 Hz. A
bandpass ﬁlter of 0.53–45 Hz and a 50-Hz notch ﬁlter were ap-
plied. Impedance at all recording electrodes was <10 kW.
EEG data analysis was conducted with the software package
Brain Vision Analyzer (Brain Products). Voltage changes of >70
μV were classiﬁed as artifacts and were not considered for fur-
ther analysis. Artifact detection was performed semiautomatically
with visual control. The continuous EEG data were rereferenced
to common average and segmented into 700-ms epochs (−200 ms
pre- to 500 ms poststimulus), baseline-corrected, and averaged.
Questionnaires. For the estimation of verbal intellectual perfor-
mance, the Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B)
was used (7). To assess the severity of nicotine dependence, we
applied the Fagerstöm Test for Nicotine Dependence (FTND) (8)
and the Questionnaire on smoking urges (QSU) (9). Alcohol use
patterns were evaluated by the Alcohol Use Disorder Identiﬁca-
tion Test (AUDIT) (10). A German version of the NEO-Five
Factor Inventory (NEO-FFI) was used to measure basic person-
ality dimensions (11). Finally, number of cigarettes smoked per
day (CPD) was assessed and pack years corrected for abstinent
periods were estimated [for details, see Brinkmeyer et al. (6)].
Statistical Analysis. Based on our previous (4) and the present re-
sults, we did a priori- and post hoc-power analyses, respectively,
for the genotype effect by using G*Power 3.0.3 (12). A priori,
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when we assumed an effect size of Cohen’s d = 0.90 (4) and
a Bonferroni-corrected α error of P = 0.0024 (21 SNPs), 147
subjects were needed to detect an genotype effect between two
groups with a power of 99% (critical F = 9.55). Post hoc, at
a signiﬁcance level of P = 0.0024, the actual effect sizes of the
TCF4 genotype effects were smaller than in our previous study
(4): rs9960767, d = 0.20; rs10401120, d = 0.19; rs17597926, d =
0.18. However, the actual power to detect TCF4 genotype effects
was good: rs9960767, 89.4%; rs10401120, 84.5%; rs17597926,
78.6% (critical F = 9.24).
All further statistical analyses were performed by using the
PASW 18.0 software package (SPSS Inc.). The demographic data,
questionnaires, and smoking variables were analyzed by one-way
analysis of variance (ANOVA) with the exception of frequency
data. Frequency data were analyzed by using χ2 tests or Fisher’s
exact test where applicable. For the primary dependent variable
of percent P50 suppression at Fz and Cz a 2*2*3 (electrode
position*genotype*smoking status) general linear model (GLM)
repeated-measures analysis of covariance (ANCOVA) was cal-
culated. The two ﬁxed factors were genotype (three- or twofold,
corresponding to a general genotypic risk model or a model
focusing on the carrier-ship of the risk allele, respectively) and
smoking status (threefold: never-smokers, light smokers, heavy
smokers), because smoking status was shown to have a strong
impact on P50 suppression (6). If the minor allele frequency
was <5% or <20 subjects of the minor allele homozygotes were
available, we compared carriers of the schizophrenia risk allele
with homozygous carriers of the non-risk allele in a two-group
design as applied before (4). Age, sex, and study site were in-
troduced as covariates because they were shown to inﬂuence P50
suppression (6, 13). Cotinine plasma level was introduced as
a covariate to control for acute nicotine effects (14). Moreover,
we introduced decimal longitude and latitude of the study cen-
ters as covariates to control for potential effects of population
stratiﬁcation because it was shown that genetic and geographic
distance was correlated along the north-south axis and, to a
lesser extent, also along the east-west axis (15). All other P50
parameters were analyzed by one-way ANCOVA with smoking,
age, sex, and study site as covariates. Conﬁrmatory statistical
comparisons were carried out at a signiﬁcance level set at P <
0.05 (two-tailed). In the primary ANCOVA analyses, the Bon-
ferroni-corrected signiﬁcance level for genotype effects was set
at P < 0.0024 (21 SNPs). In correlation analyses (according to
Pearson or Spearman where appropriate) the statistical thresh-
old was set at P < 0.00007 (two-tailed) after Bonferroni cor-
rection. Effect size calculations between two groups refer to
Cohen’s d (12). Linkage disequilibrium was estimated by using
HaploView (16). Odds ratios (OR) were calculated according to
Bland and Altman (17).
Correlations with P50 Parameters. Correlation analyses were
Bonferroni-corrected (threshold P < 7.1 × 10−5). Given that
increasing age was strongly correlated with higher P50 suppres-
sion across all parameters (difference, ratio, percent) at both
electrodes (r = 0.138–0.179, P = 3.6 × 10−9 to 1.2 × 10−14) and
also with elevated S1 P50 amplitude at Cz (r = 0.094, P = 5.7 ×
10−5), partial correlations correcting for age were conducted for
all further correlation analyses.
High verbal IQ was associated with increased S1 amplitudes
at both electrodes (Fz: r = 0.100, P = 4.9 × 10−5; Cz: r = 0.117,
P = 2.2 × 10−6). Smoking status (threefold) was associated with
S1-S2 difference (Fz: r = 0.107, P = 5.0 × 10−6; Cz: r = 0.100,
P= 1.9 × 10−5) and S1 amplitudes (Fz: r= 0.155, P= 3.1 × 10−11;
Cz: r = 0.130, P = 2.8 × 10−8), indicating lower P50 suppression
and decreased S1 amplitudes with increasing smoking severity.
Associations of P50 parameters with dimensional smoking vari-
ables were calculated only within smokers (Table S4). Higher
FTND and QSU sores, more CPDs, higher CO concentration in
respiratory air, and increased pack years were associated with
smaller S1 amplitudes. Moreover, there were negative correla-
tions between S1-S2 differences and FTND sores (and similar
trends to further smoking parameters), conﬁrming that increased
smoking behavior was associated with decreased P50 suppres-
sion, when measured by S1-S2 difference (Table S4).
Higher S1 P50 amplitudes were strongly related to greater P50
suppression across all parameters but the percent (Fz: r = 0.408,
P = 8.1 × 10−74; Cz: r = 0.338, P = 9.1 × 10−50) and ratio P50
suppression measures (Fz: r = −0.408; Cz: r = −0.338) were less
affected by S1 amplitude than the difference scores (Fz: r =
0.701, P = 1.1 × 10−268; Cz: r = 0.68, P = 1.5 × 10−249).
Moreover, percent and ratio P50 suppression were highly cor-
related with S1-S2 difference at each electrode (all r > 0.90). The
percent P50 suppression score was less affected by effects of age,
smoking, and S1 amplitude in comparison with the S1-S2 dif-
ference score, conﬁrming its applicability for the analysis of ge-
netic effects.
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Fig. S1. Pairwise linkage disequilibrium (LD) of 20 TCF4 SNPs, as measured by r2. Several markers were in strong LD. SNPs that were signiﬁcantly associated
with sensory gating are marked with a red frame.
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Fig. S2. The effects of the TCF4 SNPs rs9960767 (Upper) and rs10401120 (Lower) on percent P50 suppression of the auditory evoked potential (means and
SEM; adjusted for age, sex, study site, and cotinine plasma level, and longitude and latitude of the study center) across the electrode positions Fz and Cz. The
repeated factor electrode position interacted with the factor genotype [rs9960767: F(1,1812) = 7.10, P = 0.008, ηp2 = 0.004; rs10401120: F(1,1799) = 6.94, P = 0.008,
ηp2 = 0.004], reﬂecting that the TCF4 genotype effect was more evident at the Fz electrode.
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Fig. S3. The effects of TCF4 rs9960767 genotype on mean percent P50 suppression of the auditory evoked potential (Fz and Cz; means adjusted for age, sex,
study site, and smoking) stratiﬁed according to smoking behavior [never smokers: n = 1,023 (lifetime smoking < 10 cigarettes), light smokers: n = 466 (Fa-
gerström score < 4), and heavy smokers n = 332 (TND ≥ 4)]. A 2*3*3 (electrode position*genotype*smoking status) repeated-measures ANCOVA with age, sex,
study site, cotinine plasma level as well as longitude and latitude of the study centers as covariates revealed a signiﬁcant main effects of genotype [P = 3.1 × 10−4,
ηp2 = 0.009] and smoking [P = 0.015, ηp2 = 0.005] and a signiﬁcant interaction of the factors smoking and genotype [P = 0.007, ηp2 = 0.008].
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North Germany:
rs9960767: AA: 90.7%, AC: 9.0%, CC: 0.3%
rs10401120: CC: 93.5%, CT: 6.1%, TT: 0.3%
rs17597926: GG: 96.1%, GA: 3.5%, AA: 0.3%
rs17512836: TT: 96.1%, TC: 3.6%, CC: 0.3%
Mid-West Germany:
rs9960767: AA: 89.9%, AC: 9.3%, CC: 0.8%
rs10401120: CC: 91.7%, CT: 7.8%, TT: 0.5 %
rs17597926: GG: 94.9%, GA: 5.1%, AA: 0.0%
rs17512836: TT: 95.0%, TC: 5.0%, CC: 0.0%
South Germany:
rs9960767: AA: 87.2%, AC: 12.3%, CC: 0.4%
rs10401120: CC: 90.2%, CT: 9.5%, TT: 0.3%
rs17597926: GG: 94.0%, GA: 5.9%, AA: 0.2%
rs17512836: TT: 93.9%, TC: 5.9%, CC: 0.2%
Statistics:
rs9960767: Chi2=6.97, p=.14
rs10401120: Chi2=4.60, p=.33
rs17597926: Chi2=4.60, p=.33
rs17512836: Chi2=4.93, p=.30
Mannheim
n = 362*
*No EGG measurment
Fig. S4. TCF4 genotype frequencies across three regional clusters of study centers. TCF4 genotype frequencies did not signiﬁcantly differ between North,
Midwest, and South Germany. Germany map: Wikipedia/Creative Commons License.
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Table S1. Minor allele frequencies, tests on deviation from Hardy–Weinberg equilibrium (HWE),
and call rates for all investigated TCF4 SNPs in the total sample (n = 2,204)
Name Position ObsHET PredHET HWE Call rate, % MAF MAF-HapMap CEU Alleles
rs10401120* Intron 0.08 0.09 0.08 99.6 0.05 0.06 C:T
rs11152369 Intron 0.05 0.05 0.40 99.9 0.03 0.03 A:C
rs11874716 Intergenic 0.50 0.49 0.49 100.0 0.43 0.42 T:G
rs11875348 Intergenic 0.31 0.31 0.92 99.9 0.19 0.23 C:A
rs12966547 Intergenic 0.50 0.49 0.46 99.8 0.43 0.42 G:A
rs17511376 Intron 0.06 0.07 0.20 100.0 0.03 0.03 C:T
rs17512836*,† Intron 0.05 0.05 0.47 99.8 0.03 0.03 C:T
rs17594526 Intron 0.05 0.05 0.12 99.9 0.03 0.03 C:T
rs17594665 Intron 0.05 0.05 0.37 99.6 0.03 0.03 G:A
rs17594721 Intron 0.05 0.05 0.40 99.6 0.03 0.03 A:G
rs17596267 Intron 0.06 0.07 0.20 99.5 0.03 0.03 T:A
rs17596974 Intron 0.08 0.08 1.00 99.8 0.04 0.05 C:T
rs17597926* Intron 0.05 0.05 0.47 100.0 0.03 0.04 G:A
rs4131791 Intergenic 0.50 0.49 0.48 99.9 0.43 0.42 C:T
rs4309482‡ Intergenic 0.50 0.49 0.43 100.0 0.43 0.42 A:G
rs8092679 Intron 0.06 0.06 0.25 99.7 0.03 0.04 G:A
rs9646596 Intron 0.05 0.05 0.39 99.6 0.03 0.04 G:A
rs9951150 Intergenic 0.49 0.49 0.75 99.5 0.44 0.45 A:G
rs9953930 Intergenic 0.31 0.31 0.76 99.6 0.19 0.24 T:C
rs9960767*,§ Intron 0.11 0.11 0.17 99.7 0.06 0.07 A:C
HWE, the P value for deviation from Hardy-Weinberg equilibrium; MAF, minor allele frequency; MAF-HapMap-
CEU, minor allele frequency in the HapMap-CEU sample; ObsHET, observed heterozygosity; PredHet, predicted
heterozygosity.
*SNPs signiﬁcantly associated with sensory gating.
†Most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Ripke et al. (1).
‡Second most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Ripke et al. (1).
§Most signiﬁcant TCF4 SNP in the schizophrenia GWAS of Stefansson et al. (2) and Steinberg et al. (3).
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Table S2. Demographic data, smoking parameters, and psychometric scales of healthy volunteers grouped according to their TCF4
genotype
Measurements Risk allele carrier Nonrisk allele carrier Total F/χ2 df/dferr P ηp2
TCF4 rs9960767 genotype, CC+AC/AA
n 211 (11.6%) 1,610 (88.4%) 1,821 (100%) — — — —
Age 34.7 (0.85) 36.2 (0.33) 36.0 (0.32) 2.40 1/1,820 0.12 0.001
Years of school education 11.7 (0.11) 11.8 (0.04) 11.8 (0.04) 0.33 1/1,820 0.57 0.000
Verbal IQ* 109.9 (1.07) 109.7 (0.34) 109.7 (0.33) 0.03 1/1631 0.87 0.000
Percent male 40.8% 42.6% 42.4% 0.26 1 0.61 —
Percent smokers (never-smoker/light
smoker/heavy smoker)
56.9/25.1/18.0% 56.1/25.7/18.3% 56.2/25.6/18.2% 0.05 1 0.98 —
Current cigarettes smoked per day (CPD) 5.8 (0.63) 6.2 (0.25) 6.1 (0.23) 0.25 1/1820 0.62 0.000
Pack years†,‡ 12.7 (1.42) 14.4 (0.56) 14.2 (0.52) 1.12 1/766 0.29 0.001
Fagerström Test for Nicotine Dependence 1.28 (0.15) 1.28 (0.06) 1.28 (0.05) 0.00 1/1820 0.98 0.000
Questionnaire on smoking urges† 104.7 (4.58) 100.2 (1.58) 100.7 (1.49) 0.93 1/766 0.34 0.001
Exhaled CO, parts per million 6.2 (0.59) 6.9 (0.25) 6.8 (0.23) 0.95 1/1820 0.33 0.001
Cotinine plasma concentration, ng/mL 52.7 (7.38) 50.8 (2.42) 51.1 (2.31) 0.07 1/1820 0.80 0.000
Alcohol Use Disorder Identiﬁcation Test 4.1 (0.23) 4.0 (0.08) 4.0 (0.08) 0.13 1/1820 0.71 0.000
NEO-FFI Neuroticism 1.5 (0.06) 1.5 (0.03) 1.5 (0.03) 0.00 1/1820 0.96 0.000
Extraversion 2.6 (0.16) 2.6 (0.04) 2.6 (0.04) 0.19 1/1820 0.67 0.000
Openness to experience 2.6 (0.17) 2.6 (0.05) 2.6 (0.05) 0.00 1/1820 0.97 0.000
Agreeableness 2.8 (0.14) 2.8 (0.05) 2.8 (0.05) 0.00 1/1820 0.97 0.000
Conscientiousness 2.9 (0.16) 2.9 (0.05) 2.9 (0.05) 0.00 1/1820 0.95 0.000
TCF4 rs10401120 genotype, CT+TT/CC
n 165 (9.1%) 1,647 (90.9%) 1,812 (100%) — — — —
Age 35.1 (0.96) 36.1 (0.34) 36.0 (0.32) 0.80 1/1807 0.37 0.000
Years of school education 11.7 (0.12) 11.8 (0.04) 11.8 (0.04) 1.05 1/1807 0.31 0.000
Verbal IQ* 109.3 (1.17) 109.8 (0.34) 109.7 (0.33) 0.20 1/1624 0.66 0.000
Percent male 42.8% 42.3% 42.4% 0.01 1 0.92 —
Percent smokers (never-smoker/light
smoker/heavy smoker)
61.4/24.1/14.5% 55.7/25.7/18.6% 56.3/25.5/18.2% 2.43 1 0.30 —
Current cigarettes smoked per day (CPD) 5.3 (0.69) 6.2 (0.24) 6.1 (0.23) 1.21 1/1807 0.27 0.001
Pack years†,‡ 12.1 (1.61) 14.3 (0.54) 14.1 (0.52) 1.31 1/759 0.25 0.002
Fagerström Test for Nicotine Dependence 1.07 (0.15) 1.29 (0.06) 1.27 (0.05) 1.47 1/1807 0.23 0.001
Questionnaire on smoking urges† 105.6 (5.59) 100.1 (1.55) 100.5 (1.50) 0.97 1/759 0.33 0.001
Exhaled CO, parts per million 5.7 (0.63) 6.8 (0.24) 6.7 (0.23) 1.95 1/1807 0.16 0.001
Cotinine plasma concentration, ng/mL 47.1 (7.95) 50.9 (2.40) 50.6 (2.29) 0.22 1/1807 0.64 0.000
Alcohol Use Disorder Identiﬁcation Test 4.0 (0.26) 4.0 (0.08) 4.0 (0.08) 0.00 1/1807 0.97 0.000
NEO-FFI Neuroticism 1.4 (0.07) 1.5 (0.03) 1.5 (0.03) 0.10 1/1807 0.76 0.000
Extraversion 2.7 (0.20) 2.6 (0.03) 2.6 (0.04) 0.64 1/1807 0.42 0.000
Openness to experience 2.7 (0.21) 2.6 (0.05) 2.6 (0.05) 0.11 1/1807 0.74 0.000
Agreeableness 2.9 (0.18) 2.8 (0.05) 2.8 (0.05) 0.09 1/1807 0.76 0.000
Conscientiousness 3.0 (0.20) 2.9 (0.05) 2.9 (0.05) 0.26 1/1807 0.61 0.000
TCF4 rs17597926 genotype GA+AA/GG
n 98 (5.4%) 1,723 (94.6%) 1,821 (100%) — — — —
Age 35.6 (1.27) 36.0 (0.33) 36.0 (0.32) 0.10 1/1820 0.37 0.000
Years of school education 11.7 (0.16) 11.8 (0.04) 11.8 (0.04) 0.58 1/1820 0.45 0.000
Verbal IQ* 110.8 (1.56) 109.7 (0.34) 109.7 (0.33) 0.58 1/1619 0.45 0.000
Percent male 39.8% 42.5% 42.3% 0.27 1 0.60 —
Percent smokers (never-smoker/light
smoker/heavy smoker)
62.2/26.5/11.2% 55.8/25.7/18.5% 56.2/25.7/18.1% 3.43 1 0.18 —
Current cigarettes smoked per day (CPD) 5.1 (0.86) 6.2 (0.24) 6.1 (0.23) 1.15 1/1820 0.28 0.001
Pack years†,‡ 13.0 (2.03) 14.2 (0.54) 14.1 (0.52) 0.21 1/760 0.64 0.000
Fagerström Test for Nicotine Dependence 0.89 (0.18) 1.29 (0.06) 1.27 (0.05) 2.98 1/1820 0.08 0.002
Questionnaire on smoking urges† 109.2 (6.92) 99.9 (1.53) 100.35 (1.50) 1.59 1/760 0.21 0.002
Exhaled CO, parts per million 5.2 (0.69) 6.8 (0.24) 6.8 (0.23) 2.52 1/1820 0.11 0.001
Cotinine plasma concentration, ng/mL 47.4 (10.5) 50.8 (2.36) 50.6 (2.30) 0.11 1/1820 0.74 0.000
Alcohol Use Disorder Identiﬁcation Test 4.3 (0.35) 3.9 (0.08) 4.0 (0.08) 1.18 1/1820 0.28 0.001
NEO-FFI Neuroticism 1.5 (0.11) 1.5 (0.03) 1.5 (0.03) 0.00 1/1820 0.98 0.000
Extraversion 2.8 (0.34) 2.5 (0.04) 2.6 (0.04) 1.74 1/1820 0.19 0.001
Openness to experience 2.9 (0.35) 2.6 (0.05) 2.6 (0.05) 1.24 1/1820 0.27 0.001
Agreeableness 3.0 (0.30) 2.8 (0.05) 2.8 (0.05) 1.20 1/1820 0.27 0.001
Conscientiousness 3.1 (0.34) 2.9 (0.05) 2.9 (0.05) 0.93 1/1820 0.34 0.001
Means and SEs of means in parentheses, sex and smoking status in frequency data.
*Verbal IQ data were only available for 89.6% of the total sample.
†Only obtained in smokers.
‡Corrected by intermittent periods of life-time abstinence and accounting for variable cigarette consumption.
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Table S3. Auditory evoked potentials and P50 suppression parameters at the Fz and Cz electrode of 1,821 healthy
volunteers grouped according to their TCF4 genotype
TCF4 genotype Variable Risk allele carrier Nonrisk allele carrier F df/dferr P ηp2
rs9960767 (AC+CC/AA) S1 Fz 7.05 (0.07) 7.14 (0.03) 1.48 1/1815 0.22 0.001
Cz 6.93 (0.06) 6.98 (0.02) 0.45 1/1815 0.50 0.000
S2 Fz 4.81 (0.06) 4.72 (0.02) 2.67 1/1815 0.11 0.002
Cz 4.55 (0.05) 4.48 (0.02) 1.89 1/1815 0.17 0.001
S1-S2* Fz 2.06 (0.08) 2.39 (0.03) 15.9 1/1815 7.1 × 10−5 0.009
Cz 2.25 (0.07) 2.48 (0.02) 10.1 1/1815 0.001 0.006
S2/S1* Fz 0.71 (0.008) 0.67 (0.003) 18.9 1/1815 1.4 × 10−5 0.011
Cz 0.67 (0.007) 0.65 (0.003) 11.2 1/1815 0.001 0.006
rs10401120 (CT+TT/CC) S1 Fz 7.00 (0.08) 7.15 (0.03) 2.92 1/1802 0.09 0.002
Cz 6.9 (0.07) 6.98 (0.02) 0.57 1/1802 0.45 0.000
S2 Fz 4.79 (0.06) 4.72 (0.02) 1.19 1/1802 0.28 0.001
Cz 4.54 (0.06) 4.48 (0.02) 0.85 1/1802 0.36 0.000
S1-S2* Fz 1.98 (0.09) 2.39 (0.03) 17.6 1/1802 2.9 × 10−5 0.010
Cz 2.20 (0.08) 2.47 (0.02) 11.7 1/1802 0.001 0.007
S2/S1* Fz 0.72 (0.010) 0.67 (0.003) 18.1 1/1802 2.2 × 10−5 0.010
Cz 0.68 (0.008) 0.65 (0.003) 10.6 1/1802 0.001 0.006
rs17597926 (GA+AA/GG) S1 Fz 6.97 (0.11) 7.14 (0.03) 2.44 1/1815 0.12 0.001
Cz 6.89 (0.09) 6.98 (0.02) 1.01 1/1815 0.31 0.001
S2 Fz 4.81 (0.08) 4.73 (0.02) 0.94 1/1815 0.33 0.001
Cz 4.55 (0.07) 4.48 (0.02) 0.79 1/1815 0.37 0.000
S1-S2* Fz 1.91 (0.13) 2.38 (0.03) 13.0 1/1815 3.2 × 10−4 0.008
Cz 2.11 (0.10) 2.47 (0.02) 11.5 1/1815 0.001 0.007
S2/S1* Fz 0.73 (0.014) 0.67 (0.003) 14.2 1/1815 1.7 × 10−4 0.008
Cz 0.69 (0.011) 0.65 (0.003) 12.0 1/1815 0.001 0.007
Means and SEs of means in parentheses; adjusted for smoking status, age, sex, study site, cotinine plasma level, and longitude and
latitude of the study centers. Signiﬁcant effects are in bold.
*Smoking status as ﬁxed-factor.
Table S4. Age-corrected partial correlations of P50 amplitude (S1) and P50 suppression
parameters with smoking variables
Variable FTND score QSU CPD Pack years Exhaled CO Cotinine level
S1 amplitude Fz −0.180 −0.128 −0.161 −0.144 −0.192 −0.071
Cz −0.168 −0.146 −0.157 −0.130 −0.171 −0.047
S1-S2 Fz −0.152 −0.087 −0.125 −0.109 −0.139 −0.063
Cz −0.169 −0.122 −0.140 −0.123 −0.128 −0.057
S2/S1 Fz 0.117 0.045 0.083 0.081 0.095 0.046
Cz 0.140 0.083 0.095 0.093 0.074 0.050
%P50 Fz −0.117 −0.045 −0.083 −0.081 −0.095 −0.046
Cz −0.140 −0.083 −0.095 0.093 −0.074 −0.050
Variables only in smokers, Bonferroni-corrected threshold P < 7.1 × 10−5. Bold values are signiﬁcant at P <
7.1 × 10−5. CPD, cigarettes per day; FTND, Fagerström Test for Nicotine Dependence; QSU, Questionnaire on
smoking urges.
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Table S5. Association of low P50 suppression of the auditory evoked potential with the presence of the schizophrenia risk alleles of TCF4
polymorphisms in the general population
TCF4 genotype
Criterion for low
P50 levels* Samples Total n Low P50, n Risk-allele, n
Low P50 +
risk-allele, n Odds ratio 95% CI P†
rs9960767 (risk-allele C) 1 SD Never-smokers 1,023 124 120 17 1.228 0.707–2.131 0.274
Light smokers 466 51 53 11 2.442 1.166–5.117 0.019
Heavy smokers 332 49 38 12 3.206 1.490–6.896 0.004
Total sample 1,821 224 211 40 1.813 1.244–2.643 0.002
2 SD Never-smokers 1,023 41 120 6 1.305 0.537–3.172 0.347
Light smokers 466 15 53 4 2.983 0.915–9.730 0.079
Heavy smokers 332 19 38 6 4.053 1.441–11.400 0.013
Total sample 1,821 75 211 16 2.157 1.217–3.823 0.010
rs10401120 (risk-allele T) 1 SD Never-smokers 1,020 124 101 16 1.414 0.799–2.501 0.151
Light smokers 463 51 40 8 2.209 0.957–5.010 0.059
Heavy smokers 329 48 24 8 3.313 1.331–8.242 0.013
Total sample 1,812 223 165 32 1.834 1.212–2.776 0.004
2 SD Never-smokers 1,020 41 101 6 1.595 0.654–3.890 0.213
Light smokers 463 15 40 3 2.777 0.750–10.283 0.131
Heavy smokers 329 19 24 4 3.867 1.174–12.741 0.040
Total sample 1,812 75 165 13 2.186 1.175–4.067 0.015
rs17597926 (risk-allele A) 1 SD Never-smokers 1,023 124 61 10 1.459 0.720–2.953 0.193
Light smokers 468 50 26 5 2.101 0.755–5.842 0.132
Heavy smokers 330 47 11 5 5.496 1.606–18.810 0.011
Total sample 1,821 221 98 20 1.942 1.163–3.242 0.011
2 SD Never-smokers 1,023 41 61 4 1.754 0.604–5.093 0.224
Light smokers 468 15 26 2 2.750 0.587–12.885 0.200
Heavy smokers 330 18 11 3 7.600 1.829–31.587 0.017
Total sample 1,821 74 98 9 2.579 1.244–5.347 0.016
*Refers to a mean percent P50 suppression across Fz and Cz electrodes of 34.28% (±9.37 SD) in the present population.
†Fisher’s exact test (one-tailed). Signiﬁcant effects are in bold.
Table S6. Frequencies of TCF4 polymorphisms signiﬁcantly associated with auditory sensory gating in 1023/1020 never-smokers and 798/
792 smokers with suitable P50 suppression data
TCF4 genotype Controls/cases Allele 1, % Allele 2, %
Pair of Allele 1,
% (n)
Both alleles,
% (n)
Pair of
Allele 2, % (n) Armitage’s Trend Test
rs9960767 Controls (n = 1,023) 94.0 6.0% 88.3 (903) 11.0 (113) 0.7 (7) Odds ratio = 0.967/1.034
χ2 = 0.05 P = 0.82(Alleles A=1 and C=2) Smokers (n = 798) 94.1 5.9 88.6 (707) 10.8 (86) 0.6 (5)
Total (n = 1,821) 94.0 6.0 88.4 (1,610) 10.9 (199) 0.7 (12)
rs10401120 Controls (n = 1,020) 94.9 5.1 91.9 (919) 7.6 (96) 0.5 (5) Odds ratio = 0.846/1.183
χ2 = 1.50 P = 0.22(Alleles C=1 and T=2) Smokers (n = 792) 95.9 4.1 90.1 (728) 9.4 (60) 0.5 (4)
Total (n = 1,812) 95.3 4.7 90.9 (1,647) 8.6 (156) 0.5 (9)
rs17597926 Controls (n = 1,023) 97.0 3.0 94.0 (962) 5.8 (59) 0.2 (2) Odds ratio = 0.775/1.290
χ2 = 1.57 P = 0.21(Alleles G=1 and A=2) Smokers (n = 798) 97.7 2.3 95.4 (761) 4.5 (36) 0.1 (1)
Total (n = 1,821) 97.3 2.7 94.6 (1,723) 5.2 (95) 0.2 (3)
None of these TCF4 polymorphisms were associated with the smoking phenotype.
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